UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Autophagy as a therapeutic target in cancer

Cancer biology & therapy, 2011-01, Vol.11 (2), p.157-168

2011

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Link zum Volltext

Verfügbarkeit prüfen

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.143-143, Article 143

2019

Link zum Volltext

Verfügbarkeit prüfen

Molecular pathways: autophagy in cancer--a matter of timing and context

Clinical cancer research, 2015-02, Vol.21 (3), p.498-504

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2804-2811

2018

Link zum Volltext

Verfügbarkeit prüfen

Autophagy in malignant transformation and cancer progression

The EMBO journal, 2015-04, Vol.34 (7), p.856-880

2015

Link zum Volltext

Verfügbarkeit prüfen

Role of Autophagy in Breast Cancer

Autophagy, 2007-11, Vol.3 (6), p.610-613

2007

Link zum Volltext

Verfügbarkeit prüfen

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Genes & development, 2011-03, Vol.25 (5), p.460-470

2011

Link zum Volltext

Verfügbarkeit prüfen

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.653-663

2021

Link zum Volltext

Verfügbarkeit prüfen

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Genes & development, 2007-07, Vol.21 (13), p.1621-1635

2007

Link zum Volltext

Verfügbarkeit prüfen

Autophagy and cancer cell metabolism

Seminars in cell & developmental biology, 2012-06, Vol.23 (4), p.395-401

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Link zum Volltext

Verfügbarkeit prüfen

Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation

World journal of gastrointestinal oncology, 2014-03, Vol.6 (3), p.74-82

2014

Link zum Volltext

Verfügbarkeit prüfen

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Autophagy, 2008-07, Vol.4 (5), p.731-733

Karantza, Vassiliki

2008

Link zum Volltext

Verfügbarkeit prüfen

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells

Breast cancer research and treatment, 2015-05, Vol.151 (1), p.57-73

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1088-1088

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.1008-1008

2017

Link zum Volltext

Verfügbarkeit prüfen

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A364-A364

2021

Link zum Volltext

Verfügbarkeit prüfen

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

Molecular & cellular oncology, 2015-07, Vol.2 (3), p.e975035-e975035

2015

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Journal of clinical oncology, 2016-07, Vol.34 (21), p.2460-2467

2016

Link zum Volltext

Verfügbarkeit prüfen

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Cancer research (Chicago, Ill.), 2008-06, Vol.68 (11), p.4105-4115

2008

Link zum Volltext

Verfügbarkeit prüfen

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

The New England journal of medicine, 2022-02, Vol.386 (6), p.556-567

2022

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

The lancet oncology, 2021-04, Vol.22 (4), p.499-511

2021

Link zum Volltext

Verfügbarkeit prüfen

The interplay between autophagy and ROS in tumorigenesis

Frontiers in oncology, 2012, Vol.2, p.171

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(93)

Publikationsform

Sprache

Englisch
(101)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Autophagy as a therapeutic target in cancer

Pembrolizumab for Early Triple-Negative Breast Cancer

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Molecular pathways: autophagy in cancer--a matter of timing and context

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Autophagy in malignant transformation and cancer progression

Role of Autophagy in Breast Cancer

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea

Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis

Autophagy and cancer cell metabolism

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation

AACR Annual Meeting 2008: Autophagy in the forefront of cancer research

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells

Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B

Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

The interplay between autophagy and ROS in tumorigenesis

Suchergebnisse filtern